NCT05816681View on ClinicalTrials.gov

Assessment of Elemental Impurities Level After Multiple Administration of DWJ1230 or DWB2001 in Subjects With Functional Diarrhea or Irritable Bowel Syndrome With Predominant Diarrhea.

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 22, 2022

Primary Completion Date

February 6, 2023

Study Completion Date

April 10, 2023

Conditions
Diarrhea
Interventions
DRUG

DWJ1230

Daewoong Pharmaceutical

DRUG

DWB2001

Daewoong Bio

Trial Locations (1)

Unknown

The Catholic University of Korea, Seoul ST. Mary's Hospital., Seoul

Sponsors
All Listed Sponsors
lead

Daewoong Pharmaceutical Co. LTD.

INDUSTRY

NCT05816681 - Assessment of Elemental Impurities Level After Multiple Administration of DWJ1230 or DWB2001 in Subjects With Functional Diarrhea or Irritable Bowel Syndrome With Predominant Diarrhea. | Biotech Hunter | Biotech Hunter